Depression Disorders in Patients with Chronic Hepatitis C

Area of Science:

• Hepatology
• Psychiatry
• Pharmacology

Background:

• Chronic hepatitis C treatment historically involved interferon and ribavirin.
• Direct antiviral agents (DAA) offer improved tolerability and efficacy but face financial limitations in some regions.
• Hepatitis C patients often have a history of addiction and pre-existing depression, requiring careful psychiatric monitoring during treatment.

Purpose of the Study:

• To assess depression levels in chronic hepatitis C patients undergoing interferon therapy.
• To evaluate the impact of interferon on depression, particularly in patients with a history of addiction.
• To highlight the need for revised treatment protocols considering interferon's side effects.

Main Methods:

• Patients with chronic hepatitis C on interferon therapy were categorized into three groups: never addicts, former addicts in abstinence, and those on replacement therapy (methadone/buprenorphine).
• Beck's Depression Inventory was administered to all participants before and after interferon treatment.
• Statistical analysis was performed to compare depression levels pre- and post-therapy across groups.

Main Results:

• A significant proportion of patients with a history of addiction or on replacement therapy presented with mild to moderate depression prior to interferon treatment.
• Interferon therapy led to a statistically significant increase in severe depression among these patient groups.
• No significant increase in severe depression was observed in patients without a history of addiction.

Conclusions:

• Interferon therapy can exacerbate depression in patients with chronic hepatitis C, especially those with a history of substance abuse.
• The findings underscore the necessity for developing and implementing alternative hepatitis C therapies with improved safety profiles.
• Close collaboration between hepatologists and psychiatrists is crucial for effective patient management and monitoring during treatment.